Skip to content

Comparison of Haemostatic Effects of Tranexamic Acid, Baricitinib and Baricitinib Sequential with Tranexamic Acid in Intervertebral Foramen Approach Lumbar Interbody Fusion Surgery: A Prospective, Double-Blind, Randomised Controlled Clinical Study

Comparison of Haemostatic Effects of Tranexamic Acid, Baricitinib and Baricitinib Sequential with Tranexamic Acid in Intervertebral Foramen Approach Lumbar Interbody Fusion Surgery: A Prospective, Double-Blind, Randomised Controlled Clinical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120888
Enrollment
Unknown
Registered
2026-03-22
Start date
2026-03-22
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative diseases of the lumbar spine

Interventions

Tranexamic acid group:On the evening prior to surgery at 22:30, administer 2 ml of normal saline solution by intramuscular injection. Fifteen minutes before skin incision, administer TXA at 15 mg/kg b
Bachu Ting Group:On the evening prior to surgery at 22:30, administer 1U of bacitracin (powder, 1U/vial) + 2ml saline solution by intramuscular injection. Fifteen minutes before skin incision, adminis

Sponsors

West China Tianfu Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with severe intervertebral disc protrusion, lumbar spinal canal stenosis, symptomatic lumbar spondylolisthesis, etc., who need to undergo TLIF surgery and are first-time patients who have undergone lumbar surgery; 2. Patients aged 18 years or older and 80 years or younger; 3. Patients agree to participate in this study and sign the relevant informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with severe underlying diseases such as cardiovascular and cerebrovascular disorders who are not suitable for surgery; 2. Patients with severe anemia or coagulation dysfunction before the operation; 3. Patients allergic to TXA or batroxobin; 4. Patients with severe liver or kidney dysfunction; 5. Patients with a history of thrombosis; 6. Patients who are still taking anticoagulant drugs (such as aspirin) within two weeks before the operation; 7. Patients with intraoperative dural injury and cerebrospinal fluid leakage.

Design outcomes

Primary

MeasureTime frame
TBL on the first, second and third days post-surgery;Intraoperative blood loss;

Secondary

MeasureTime frame
Postoperative occult blood loss;Postoperative fibrinolysis and inflammatory markers;Total postoperative drainage volume;Postoperative hospital stay duration;Postoperative complications;

Countries

China

Contacts

Public ContactLiu Li

West China Tianfu Hospital, Sichuan University

liuli_guke@163.com+86 180 3054 8634

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026